Showing 1 - 20 results of 26 for search 'Per Pfeiffer', query time: 0.05s
Refine Results
-
1
-
2
How to select cancer patients for immunotherapy by Per Pfeiffer, Camilla Qvortrup, Karin Holmskov Hansen
Published 2021-01-01
Article -
3
Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data by Torben Frøstrup Hansen, Camilla Qvortrup, Per Pfeiffer
Published 2021-03-01
Article -
4
-
5
Evaluating the efficacy and safety of neoadjuvant pembrolizumab in patients with stage I–III MMR-deficient colon cancer: a national, multicentre, prospective, single-arm, phase II... by Ismail Gögenur, Per Pfeiffer, Tobias Freyberg Justesen, Line Schmidt Tarpgaard, Camilla Qvortrup
Published 2023-06-01
Article -
6
-
7
Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis by Martin Graversen, Sönke Detlefsen, Jon Kroll Bjerregaard, Claus Wilki Fristrup, Per Pfeiffer, Michael Bau Mortensen
Published 2018-06-01
Article -
8
-
9
-
10
High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. by Christina Siesing, Halfdan Sorbye, Anca Dragomir, Per Pfeiffer, Camilla Qvortrup, Fredrik Pontén, Karin Jirström, Bengt Glimelius, Jakob Eberhard
Published 2017-01-01
Article -
11
A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study by Martina Eriksen, Per Pfeiffer, Kristoffer Staal Rohrberg, Christina Westmose Yde, Lone Nørgård Petersen, Laurids Østergaard Poulsen, Camilla Qvortrup
Published 2022-12-01
Article -
12
TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trialResearch in context by Lene Baeksgaard Jensen, Mette Yilmaz, Marianne Nordsmark, Sören Möller, Ida Coordt Elle, Morten Ladekarl, Camilla Qvortrup, Per Pfeiffer
Published 2024-04-01
Article -
13
Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy f... by Stine Braendegaard Winther, Pia Österlund, Åke Berglund, Bengt Glimelius, Camilla Qvortrup, Halfdan Sorbye, Per Pfeiffer, - on behalf of the Academy of Geriatric Cancer Research (AgeCare)
Published 2017-08-01
Article -
14
Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer by Karen-Lise Garm Spindler, Christina Demuth, Boe Sandahl Sorensen, Julia S Johansen, Dorte Nielsen, Niels Pallisgaard, Estrid Hoegdall, Per Pfeiffer, Benny Vittrup Jensen
Published 2018-11-01
Article -
15
Consequences of a high incidence of microsatellite instability and BRAF‐mutated tumors: A population‐based cohort of metastatic colorectal cancer patients by Kristine Ø. Aasebø, Anca Dragomir, Magnus Sundström, Artur Mezheyeuski, Per‐Henrik Edqvist, Geir Egil Eide, Fredrik Ponten, Per Pfeiffer, Bengt Glimelius, Halfdan Sorbye
Published 2019-07-01
Article -
16
High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Met... by Halfdan Sorbye, Anca Dragomir, Magnus Sundström, Per Pfeiffer, Ulf Thunberg, Monica Bergfors, Kristine Aasebø, Geir Egil Eide, Fredrik Ponten, Camilla Qvortrup, Bengt Glimelius
Published 2015-01-01
Article -
17
miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan. by Jakob V Schou, Simona Rossi, Benny V Jensen, Dorte L Nielsen, Per Pfeiffer, Estrid Høgdall, Mette Yilmaz, Sabine Tejpar, Mauro Delorenzi, Mogens Kruhøffer, Julia S Johansen
Published 2014-01-01
Article -
18
Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study. by Line S Tarpgaard, Tormod K Guren, Bengt Glimelius, Ib J Christensen, Per Pfeiffer, Elin H Kure, Halfdan Sorbye, Tone Ikdahl, Mette Yilmaz, Julia S Johansen, Kjell Magne Tveit
Published 2014-01-01
Article -
19
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01) by Louise Skau Rasmussen, Stine B. Winther, Inna M. Chen, Britta Weber, Lise Ventzel, Gabor Liposits, Julia Sidenius Johansen, Sönke Detlefsen, Ida Egendal, Susy Shim, Signe Christensen, Per Pfeiffer, Morten Ladekarl
Published 2023-06-01
Article -
20
The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer R... by Gabor Liposits, Halla Skuladottir, Jesper Ryg, Stine Brændegaard Winther, Sören Möller, Eva Hofsli, Carl-Henrik Shah, Laurids Østergaard Poulsen, Åke Berglund, Camilla Qvortrup, Pia Osterlund, Julia S. Johansen, Bengt Glimelius, Halfdan Sorbye, Per Pfeiffer
Published 2022-09-01
Article